TORVUTATUG SAMROTECAN
UNII E5QZ8ZF3HE

Substance Identification & Data

This profile provides standardized clinical and technical data for Torvutatug Samrotecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) E5QZ8ZF3HE.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2975630-26-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

E5QZ8ZF3HE

CAS Registry Number

2975630-26-1

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TORVUTATUG SAMROTECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C200057

National Cancer Institute reference terminology for clinical and research data.

INN ID

13421

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

NO-25

Identifier assigned by the United States Adopted Names Council.

Substance Type

Torvutatug Samrotecan

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Torvutatug Samrotecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Torvutatug Samrotecan

Common Names & Synonyms

AZD 5335 [WHO-DD]

H-gamma1 heavy chain Homo sapiens (1-449) [VH (Homo sapiens IGHV6-1*01 (98.0%) -(IGHD) -IGHJ4*01 (100%), CDRIMGT [10.9.9] (26-35.53-61.100-108)) (1-119) -Homo sapiens IGHG1*03 (100%) G1m3, nG1m1 CH1 R120, CH3 E12, M14 (CH1 R120 (216) (120-217), hinge 1-15 (218-232), CH2 (233-342), CH3 E12 (358), M14 (360) (343-447), CHS (448-449)) (120-449)], (222-215')-disulfide with L-kappa light chain Homo sapiens (1'-215') [V-KAPPA (Homo sapiens IGKV1-5*03 (98.9%) -IGKJ4*01 (100%), CDR-IMGT [6.3.10] (27'-32'.50'-52'.89'-98')) (1'-108') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (154'), V101 (192')) (109'-215')]; dimer (228-228'':231-231'')-bisdisulfide, produced in a cell line from Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa; substituted at the eight sulfur atoms of L-cysteinyl residues 222, 228, 231, 215', 222'', 228'', 231'' and 215''' with (3RS)-1-[(2S,5S)-1-{[(9S)-9-ethyl-9-hydroxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12Hbenzo[ de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]amino}-2-methyl-1,4,7,35-tetraoxo-5-(propan-2-yl)-10,13,16,19,22,25,28,31-octaoxa-3,6,34-triazaheptatriacontan-37-yl]-2,5-dioxopyrrolidin-3-yl (samrotecan) groups

Immunoglobulin G1, anti-(human folate receptor α) (human monoclonal INT-019 γ1-chain), complex with human monoclonal INT-019 κ-chain, dimer, octakis(thioether) with N-[31-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1,29-dioxo-4,7,10,13,16,19,22,25-octaoxa-...

TORVUTATUG SAMROTECAN [USAN]

immunoglobulin G1-kappa, anti-[Homo sapiens FOLR1 (folate receptor 1, folate receptor alpha, FR-alpha, adult folate-binding protein, FBP, ovarian tumor-associated antigen MOv18)], Homo sapiens monoclonal antibody; conjugated on eight cysteinyl residues to samrotecan, comprising a linker and a camptothecin derivative (exatecan) (torvutatug samrotecan)

torvutatug samrotecan [INN]